Impact of CYP2D6 genotype and co-medication with paroxetine and clarithromycin on clomiphene metabolism in vivo

被引：0
|
作者：
Muerdter, T. [1 ,2 ]
Lehr, T. [3 ]
Igel, S. [1 ,2 ]
Kroener, P. [1 ,2 ]
Ganchev, B. [1 ,2 ]
Schaeffeler, E. [1 ,2 ]
Boehmer, G. [4 ]
Sonnenberg, M. [1 ,2 ]
Brauch, H. [1 ,2 ]
Kerb, R. [1 ,2 ]
Schwab, M. [1 ,2 ,4 ]
机构：
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[2] Univ Tubingen, Stuttgart, Germany
[3] Univ Saarland, Klin Pharm, Saarbrucken, Germany
[4] Univ Klinikum Tubingen, Klin Pharmakol Abt, Tubingen, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2016年 / 389卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
021
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [21] CYP2D6 Genotype Dependent Oxycodone Metabolism in Postoperative Patients
    Stamer, Ulrike M.
    Zhang, Lan
    Book, Malte
    Lehmann, Lutz E.
    Stuber, Frank
    Musshoff, Frank
    PLOS ONE, 2013, 8 (03):
  • [22] Metabolism of desipramine in Japanese psychiatric patients:: The impact of CYP2D6 genotype on the hydroxylation of desipramine
    Shimoda, K
    Morita, S
    Hirokane, G
    Yokono, A
    Someya, T
    Takahashi, S
    PHARMACOLOGY & TOXICOLOGY, 2000, 86 (06): : 245 - 249
  • [23] Dynamics and persistence of CYP2D6 inhibition by paroxetine
    Jurica, J.
    Zourkova, A.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (04) : 294 - 300
  • [24] The association between CYP2D6 genotype and switching antipsychotic medication to clozapine
    Jochem G. Gregoor
    Karen van der Weide
    Jan van der Weide
    Harold J. G. M. van Megen
    Antoine C. G. Egberts
    Eibert R. Heerdink
    European Journal of Clinical Pharmacology, 2013, 69 : 1927 - 1932
  • [25] The association between CYP2D6 genotype and switching antipsychotic medication to clozapine
    Gregoor, Jochem G.
    van der Weide, Karen
    van der Weide, Jan
    van Megen, Harold J. G. M.
    Egberts, Antoine C. G.
    Heerdink, Eibert R.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (11) : 1927 - 1932
  • [26] An in vivo comparison of paroxetine and fluvoxamine: Effects on CYP1A2 and CYP2D6 activities.
    Ozdemir, V
    Naranjo, CA
    Shulman, RW
    Herrmann, N
    Sellers, EM
    Kalow, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII47 - PII47
  • [27] The relationship between plasma concentration of paroxetine and CYP2D6 genotype in Japanese psychiatric patients
    Ueda, M
    Hirokane, G
    Morita, S
    Okawa, M
    Shimoda, K
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (03) : 181 - 181
  • [28] Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism
    Dorado, Pedro
    Gonzalez, Idilio
    Naranjo, Maria Eugenia G.
    de Andres, Fernando
    Penas-Lledo, Eva Maria
    Calzadilla, Luis Ramon
    LLerena, Adrian
    OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2017, 21 (01) : 17 - 26
  • [29] The relationship between plasma concentration of paroxetine and CYP2D6 genotype in Japanese psychiatric patients
    Ueda, M
    Hirokane, G
    Morita, S
    Yokono, A
    Okawa, M
    Shimoda, K
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S223 - S223
  • [30] CYP2D6 genotype and tamoxifen response
    James M Rae
    Matthew P Goetz
    Daniel F Hayes
    James N Ingle
    Lang Li
    Anna Maria Storniolo
    Vered Stearns
    David A Flockhart
    Breast Cancer Research, 7
12345